Superficial Vein Thrombosis of Lower Limbs: Influence of Factor V Leiden, Factor II G20210A and Overweight

Philippe de Moerloose; Robert Wutschert; Monica Heinzmann; Thomas Perneger; Guido Reber; Henri Bounameaux

doi:10.1055/s-0037-1615180

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1998; 80(02): 239-241
DOI: 10.1055/s-0037-1615180

Rapid Communication

Schattauer GmbH

Superficial Vein Thrombosis of Lower Limbs: Influence of Factor V Leiden, Factor II G20210A and Overweight

Philippe de Moerloose

¹Division d’Angiologie et d’Hémostase, Hôpital Universitaire Genève, Genève, Switzerland and Institut de Médecine Sociale et Préventive, Université de Genève, Switzerland

,

Robert Wutschert

¹Division d’Angiologie et d’Hémostase, Hôpital Universitaire Genève, Genève, Switzerland and Institut de Médecine Sociale et Préventive, Université de Genève, Switzerland

,

Monica Heinzmann

¹Division d’Angiologie et d’Hémostase, Hôpital Universitaire Genève, Genève, Switzerland and Institut de Médecine Sociale et Préventive, Université de Genève, Switzerland

,

Thomas Perneger

¹Division d’Angiologie et d’Hémostase, Hôpital Universitaire Genève, Genève, Switzerland and Institut de Médecine Sociale et Préventive, Université de Genève, Switzerland

,

Guido Reber

¹Division d’Angiologie et d’Hémostase, Hôpital Universitaire Genève, Genève, Switzerland and Institut de Médecine Sociale et Préventive, Université de Genève, Switzerland

,

Henri Bounameaux

¹Division d’Angiologie et d’Hémostase, Hôpital Universitaire Genève, Genève, Switzerland and Institut de Médecine Sociale et Préventive, Université de Genève, Switzerland

› Author Affiliations

Abstract

Summary

Superficial vein thrombosis (SVT) has been reported in patients with thrombophilia. In the present unmatched case-control study, the two most common thrombophilic abnormalities (factor V Leiden and factor II G20210A) were searched for in 112 consecutive patients with SVT of lower limbs and in 180 healthy donors. FV Leiden was present in 16/112 (14.3%) SVT patients and 11/180 (6.1%) controls (odds ratio 2.51, 95% CI 1.04-6.24) and FII G20210A in 4/112 (3.6%) patients and 2/180 (1.1%) controls (OR 3.28, 95% CI 0.46-36.84). In addition, body mass index (BMI) ≥28 kg/m² was also associated with SVT (OR 2.81, 95% CI 1.60-5.00). After adjustement for BMI ≥28 kg/m², the association between FV Leiden and SVT remained strong though no longer statistically significant. Among patients with SVT, the presence of FV Leiden was independently associated with the absence of varicose veins (OR 4.62, 95% CI 1.25-18.0) and with a BMI ≥28 kg/m² (OR 3.74, 95% CI 1.05-15.1). In conclusion, both FV Leiden and overweight seem to predispose to SVT, a finding that should be confirmed in larger studies.

Full Text

References

References
1 Engesser L, Broekmans AW, Briët E, Brommer J-P, Bertina RM. Hereditary protein S deficiency: clinical manifestations.. Ann Intern Med 1987; 106: 677-82.
2 Pabinger I. Schneider B for the Gesellschaft für Thrombose und Haemostaseforschung (GTH) study group on natural inhibitors.. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency.. Arterioscler Thromb Vasc Biol 1996; 16: 742-8.
3 Lane D, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlbäck B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U. Inherited thrombophilia: Part 2.. Thromb Haemost 1996; 76: 824-34.
4 Samama MM, Simon D, Horellou MH, Trossaërt M, Elalamy I, Conard J. Diagnosis and clinical characteristics of inherited activated protein C resistance.. Haemostasis 1996; 26 (Suppl. 04) 315-30.
5 Tormene D, Scudeller A, Sardella C, Luni S, Gavasso S, Marchesan D, Scarano L, Zanon E, Simioni P, Prandoni P, Girolami A. Activated protein C resistance due to factor V Leiden mutation: a study of 95 families.. Thromb Haemost suppl 1997; p 311 (abst).
6 Martinelli I, De Stefano V, Taioli E, Rossi V, Crosti F, Paciaroni K, Leone G, Mannucci PM. APC resistance carries a lower risk of thrombosis in comparison to the other inherited thrombophilic defects.. Thromb Haemost suppl 1997; p 373 (abst).
7 Dahlbäck B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism.. Blood 1995; 85: 607-14.
8 Poort RS, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.. Blood 1996; 88: 3698-703.
9 de Moerloose Bounameaux H, Mannucci PM. Screening tests for thrombophilic patients: which tests, for which patient, by whom, when and why?. Semin Thromb Haemos. in press.
10 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RH, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation Factor V associated with resistance to activated protein C.. Nature 1994; 369: 64-7.
11 Stevens J, Cai J, Pamuk ER, Williamson DF, Thun MJ, Wood JL. The effect of age on the association between body-mass index and mortality.. N Engl J Med 1998; 338: 1-7.
12 Manson JE, Willett WC, Stampfer MJ. et al. Body weight and mortality among women.. N Engl J Med 1995; 333: 677-85.
13 Samlaska CP, James WD. Superficial thrombophlebitis. II. Secondary hypercoagulable states.. J Am Acad Dermatol 1990; 23: 1-18.
14 Vanitallie TB. Obesity: adverse effects on health and longevity.. Am J Clin Nutr 1979; 32: 2723-33.
15 Garbaciak JA, Richter M, Miller S, Barton JJ. Maternal weight and pregnancy complications.. Am J Obstet Gynecol 1985; 152: 238-45.
16 Coon WW. Risk factors in pulmonary embolism.. Surg Gyn Obstet 1976; 143: 385-90.
17 Goldhaber SZ, Savage DD, Garrison RJ, Castelli WP, Kannel WB, McNamara PM, Gherardi G, Feinleib M. Risk factors for pulmonary embolism. The Framingham study.. Am J Med 1983; 74: 1023-8.
18 Goldhaber SZ, Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH. A prospective study of risk factors for pulmonary embolism in women.. JAMA 1997; 277: 642-5.
19 Primrose JN, Davies JA, Prentice CRM, Hughes R, Johnston D. Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity.. Thromb Haemost 1992; 68: 396-9.
20 Mateo J, Oliver A, Borell M, Sala N, Fontcuberta J. and the EMET group.. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thrombosis – Results of the Spanish Multi-centric Study on Thrombophilia (EMET study).. Thromb Haemost 1997; 77: 444-51.